Karo Bio, 4D Science Team Up On Treatments For Fibrotic Diseases

Karo Bio and 4D Science have entered a collaboration to develop treatments for fibrotic diseases. The partnership is based on the recent findings of a research group led by Jörg Distler, M.D., CEO and founder of 4D Science.

The group discovered that a specific nuclear receptor plays a key role in the pathogenesis of fibrotic diseases. The collaboration will initially focus on generating additional data to further validate the nuclear receptor as a target in fibrosis and demonstrate its druggability. Karo Bio will carry out the collaboration work within the scope of its current operations. The two firms will share costs and rewards for the program.

Dr. Distler is research group leader at the Department of Internal Medicine 3 and Center for Clinical Immunology at the University of Erlangen-Nuremberg focusing on translational fibrotic disease research. According to the company, 4D Science has a broad range of fibrotic disease models that are used by the pharmaceutical industry to evaluate drug candidates.

Karo Bio runs drug development projects mainly within the therapeutic areas neuropsychiatry, inflammation, autoimmune diseases, and cancer.

This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.